NCT02997228 2026-04-13
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
National Cancer Institute (NCI)
Phase 3 Active not recruiting
National Cancer Institute (NCI)
University of Pittsburgh
Gruppo Oncologico del Nord-Ovest
Exelixis
Hoffmann-La Roche